Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Non-Current Liabilities (2016 - 2025)

RedHill Biopharma has reported Total Non-Current Liabilities over the past 15 years, most recently at $1.9 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 268.99% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, up 268.99% year-over-year, with the annual reading at $1.9 million for FY2025, 268.99% up from the prior year.
  • Total Non-Current Liabilities was $1.9 million for Q4 2025 at RedHill Biopharma, up from $500000.0 in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $94.9 million in Q2 2021 and troughed at $500000.0 in Q2 2025.
  • The 5-year median for Total Non-Current Liabilities is $2.6 million (2023), against an average of $21.7 million.
  • Year-over-year, Total Non-Current Liabilities tumbled 89.86% in 2023 and then soared 268.99% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $90.8 million in 2021, then crashed by 89.19% to $9.8 million in 2022, then tumbled by 89.86% to $995000.0 in 2023, then tumbled by 49.45% to $503000.0 in 2024, then soared by 268.99% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Total Non-Current Liabilities are $1.9 million (Q4 2025), $500000.0 (Q2 2025), and $503000.0 (Q4 2024).